Milestone Pharmaceuticals Inc

+0.01 (+0.24%)
5:46:16 PM EDT: $4.29 +0.18 (+4.38%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)141.25M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$1.17 Million
Adjusted EPS-$0.34
See more estimates
10-Day MA$3.84
50-Day MA$4.06
200-Day MA$6.01
See more pivots

Milestone Pharmaceuticals Inc Stock, NASDAQ:MIST

1111 Dr. Frederik-Philips Boulevard, Suite 420, Montr?©al, Qu?©bec H4M 2X6
Phone: +1.514.336.0444
Number of Employees: 29


Milestone Pharmaceuticals, Inc. engages in the development and commercialization of cardiovascular medicines. Its lead product candidate etripamil, is a novel, potent and short-acting calcium channel blocker that is designed as a rapid-onset nasal spray to be self-administered by patients. It develops etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, rapid ventricular rate, and other cardiovascular indications. The company was founded by Philippe Douville and Philippe Lamarre in 2003 and is headquartered in Montreal, Canada.